Type 2 diabetes is known to have increased prevalence of lipid abnormalities leading to high risk of cardiovascular diseases (CVD). Diabetic patients are at more risk for altered lipid profile than normoglycemic persons. Glycated hemoglobin (HbA1c) is a routinely used marker for long-term glycemic controland as a screening tool for the diagnosis of diabetes. A value over 6% gives an indication of altered glucose control. Also, HbA1c nowadays is considered an independent risk factor for CVD. In this study association between Glycated haemoglobin (HbA1c) and diabetic dyslipidemia was found. Venous blood samples were collected from 113 type 2 diabetic patients. The whole blood and serum were analyzed for HbA1c, fasting blood sugar (FBS) and lipid profile using cobas c 501 system. The statistical analysis was done by SPSS statistical package version 21. HbA1c showed significant correlations with total cholesterol (TC), triglycerides (TG), low density lipoprotein cholesterol (LDL-C) and TC/HDL-C ratio. Patients with HbA1c value > 7.0% had significantly higher value of TC, Triacylglycerol (TG), VLDL-C, LDL-C and TC/HDL-C ratio as compared to the patients with HbA1c ≤ 7.0%. However, there was no significant difference in value of HDL-C between two groups. Thus,HbA1c can be used as a potential biomarker for predicting dyslipidemia in type 2 diabetic patients.

Keywords: Diabetes mellitus, Dyslipidemia, Glycated hemoglobin, Lipid Profile.

1. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2010;33:S62–9.
2. Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management. Drugs. 2013;73:327–39.
3. LeRoith D, Smith DO. Monitoring glyc-emic control: the cornerstone of diabetes care. Clin. Ther. 2005;27:1489–99.
4. Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Svensson A-M, Gudbjörnsdóttir S, et al. New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). J. Intern. Med. 2010;268:471–82.
5. Hu Y, Liu W, Chen Y, Zhang M, Wang L, Zhou H, et al. Combined use of fasting plasma glucose and glycated hemoglobin A1c in the screening of diabetes and impaired glucose tolerance. Acta Diabetol. 2010;47:231–6.
6. Gudbjörnsdottir S, Eliasson B, Eeg-Olofsson K, Zethelius B, Cederholm J, National Diabetes Register (NDR). Additive effects of glycaemia and dyslipidaemia on risk of cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register. Diabetologia. 2011;54:2544–51.
7. Van ’t Riet E, Rijkelijkhuizen JM, Alssema M, Nijpels G, Stehouwer CDA, Heine RJ, et al. HbA1c is an independent predictor of non-fatal cardiovascular disease in a Caucasian population without diabetes: a 10-year follow-up of the Hoorn Study. Eur. J. Prev. Cardiol. 2012;19:23–31.
8. Bucolo G, David H. Quantitative determi-nation of serum triglycerides by the use of enzymes. Clin. Chem. 1973;19:476–82.
9. Sugiuchi H, Uji Y, Okabe H, Irie T, Uekama K, Kayahara N, et al. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. Clin. Chem. 1995;41:717–23.
10. Roeschlau P, Bernt E, Gruber W. Enzymatic determination of total cholesterol in serum. Z. Für Klin. Chem. Klin. Biochem. 1974;12:226.
11. Lema OE, Carter JY, Arube PA, Munafu CG, Wangai MW, Rees PH. Evaluation of the alkaline haematin D-575 method for haemoglobin estimation in east Africa. Bull. World Health Organ. 1994;72:937–41.
12. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–421.
13. Comparison of Diabetes Diagnostic Categories in the U.S. Population According to 1997 American Diabetes Association and 1980–1985 World Health Organization Diagnostic Criteria | Diabetes Care [Internet]. [cited 2016 Oct 6]. Available from: http://care.diabetesjournals.org/content/20/12/1859.short
14. Gallagher EJ, Le Roith D, Bloomgarden Z. Review of hemoglobin A(1c) in the management of diabetes. J. Diabetes. 2009;1:9–17.
15. Berg AH, Sacks DB. Haemoglobin A1c analysis in the management of patients with diabetes: from chaos to harmony. J. Clin. Pathol. 2008;61:983–7.
16. Ahmad Khan H. Clinical significance of HbA1c as a marker of circulating lipids in male and female type 2 diabetic patients. Acta Diabetol. 2007;44:193–200.
17. Pérez-López FR, Larrad-Mur L, Kallen A, Chedraui P, Taylor HS. Gender Differences in Cardiovascular Disease: Hormonal and Biochemical Influences. Reprod. Sci. Thousand Oaks Calif. 2010;17:511–31.
18. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat. Clin. Pract. Endocrinol. Metab. 2009;5:150–9.
19. Ghazanfari Z, Haghdoost AA, Alizadeh SM, Atapour J, Zolala F. A Comparison of HbA1c and Fasting Blood Sugar Tests in General Population. Int. J. Prev. Med. 2010;1:187–94.
20. Adebisi SA, Oghagbon EK, Akande TM, Olarinoye JK. Glycated haemoglobin and glycaemic control of diabetics in Ilorin. Niger. J. Clin. Pract. 2009;12:87–91.
21. K. P, Kunikullaya U. K, Goturu J. Glycosylated Haemoglobin (HbA1c) - A Marker of Circulating Lipids in Type 2 Diabetic Patients. J. Clin. Diagn. Res. JCDR. 2014;8:20–3.

Dinesh Bure

Assistant Professor, Department of Biochemistry,

B.K.L Walawalkar Rural Medical College and Hospital, Sawarde, Maharashtra

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.